Kenvue (KVUE) Stock Price, Fundamentals & Analysis

What KVUE does

Kenvue (KVUE) is a consumer health stock listed on the US market in the Consumer Defensive sector, specifically the Household & Personal Products industry. Headquartered in Summit, United States, it operates across the United States, the rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company is organised into three segments — Self Care, Skin Health and Beauty, and Essential Health — and sells well-known brands such as Benadryl, Tylenol, Neutrogena, BAND-AID, Listerine, and Johnson's. With 21,780 employees, Kenvue generates revenue from over-the-counter medicines, naturally inspired self-care products, digital diagnostics, and telemedicine.

Key numbers explained

• The current price is 17.67 USD, down 1.06% today, with a 52-week range of 14.02 – 20.13 and a 5.9% price change over the last year.
• The trailing P/E ratio of 20.8 shows how much investors pay per dollar of recent earnings; the lower forward P/E ratio of 14.3 reflects expectations for future earnings.
• Earnings per share for the trailing 12 months is 0.85 USD, while the dividend yield of 4.7% indicates the annual dividend as a percentage of the share price.
• The exDividendDate is 21 sept. 2026, and 98% of earnings are paid out as dividends, meaning nearly all profit is returned to shareholders.
• Beta of 0.43 suggests the stock tends to move less than the overall market, which can appeal to risk-averse investors.
• Market capitalisation stands at 33.94 mld. USD, placing it among large-cap companies, and it is part of the S&P 500.
• Revenue for the trailing 12 months is 15.41 mld. USD, growing 3% year over year, with a profitMargin of 10.8% and an operatingMargin of 19.4%.
• The debt-to-equity ratio of 81.6 shows the level of debt relative to shareholder equity, while priceToBook of 3.22 compares the market price to the company's book value.

Recent news

Recent headlines note that Consumer Stocks declined on Wednesday afternoon, while market chatter reports that Kimberly-Clark is offering concessions for EU approval of its $40 billion deal for Kenvue. Other stories highlight Kenvue as a high-yield dividend stock and include a dedicated dividend analysis, as well as a piece on Kimberly-Clark lining up assets for the deal review.

What to watch

Investors tracking Kenvue often watch Consumer Defensive names like Procter & Gamble (PG), Hormel Foods (HRL), and Bunge Global (BG) for sector context. The debt-to-equity ratio, dividend yield, and upcoming nextEarningsDate of 5 nov. 2026 are common focus points. Broader factors such as consumer spending trends, regulatory approvals for major deals, and movements in the S&P 500 can also influence the stock.